Sumitomo Chemical India Limited reported an 8.2% rise in net profit to ₹5,431.39 million for the financial year ended March 31, 2026, compared to ₹5,019.48 million in the previous year. Revenue from operations increased to ₹31,857.62 million from ₹30,903.69 million in FY25, while total income grew to ₹33,318.26 million. The board has recommended a dividend of ₹1.3 per equity share, aggregating ₹648.89 million, subject to shareholder approval at the ensuing Annual General Meeting.

Financial Performance

For the quarter ended March 31, 2026, the company recorded a profit of ₹1,106.10 million, a significant increase from ₹748.26 million in the preceding quarter ended December 31, 2025. Revenue for the quarter stood at ₹6,714.91 million. The company’s agro-chemicals segment remains its sole reportable segment, with performance influenced by seasonal monsoon conditions.

The auditors' reports for both standalone and consolidated financial results were unmodified and without qualifications. BSR & Co. LLP, Chartered Accountants, audited the results.

Segment and Operational Details

The company noted that its business is seasonal and dependent on climatic conditions. In October 2022, the Government of India issued a notification mandating that Glyphosate, a key product, be used only through Pest Control Operators. Industry petitions challenging this notification are currently being heard by the Delhi High Court, and the government counsel has stated the notification will not be implemented until the petitions are disposed of.

Exceptional Items

During the quarter ended December 31, 2025, the company recognized an exceptional item of ₹151.86 million in standalone results and ₹161.11 million in consolidated results. This charge relates to the incremental impact of the four Labour Codes notified by the Government of India in November 2025, which the company assessed as regulatory-driven and non-recurring.

Sumitomo Chemical India reported its highest-ever profitability performance in financial year 2026, navigating a challenging agrochemical industry landscape characterized by adverse weather and regulatory constraints. The company achieved a profit after tax (PAT) of INR543 crores, a growth of more than 7% year-on-year, while profit before tax (PBT) before exceptional items grew by over 9%. This performance was supported by a gross profit margin of 42% and an EBITDA margin of 20.7%, with net profit margins reaching 16.8%, all record levels in the company's history.

For the quarter ended March 31, 2026, revenue from operations stood at INR684 crores, a 1% increase year-on-year. Gross profit for the quarter grew 6% to INR289 crores with a margin of 42.3%, while EBITDA rose 12% to INR134 crores. PAT for the quarter increased 12% to INR111 crores. On a full-year basis, revenue from operations was INR3,238 crores, up 3% year-on-year. The company’s business mix improved, with branded formulations constituting 81% of domestic sales. Herbicides registered strong growth of 19% for the year, while metal phosphates grew 11%.

Financial Performance Summary

The company’s balance sheet remained essentially debt-free, with cash and cash equivalents of approximately INR2,113 crores as of March 31, 2026. Return on capital employed improved to 31% from 29% in the previous year, and net worth grew to INR3,394 crores, a 17% year-on-year increase. The company recorded an exceptional charge of INR16.1 crores in FY26 regarding newly notified labor codes.

Management highlighted that the Indian agrochemical industry faced one of its most challenging years due to excess rainfall during the kharif season and regulatory constraints affecting biostimulants. Despite these headwinds, the company maintained pricing integrity and recorded negligible returns of goods. Looking ahead to FY27, the company expressed cautious optimism, citing resilient agriculture sector demand but noting risks related to monsoon forecasts and geopolitical tensions impacting costs. The company is calibrating inventory buildup and channel stocking based on a normal kharif season assumption.

Significant leadership transitions were announced, effective September 1, 2026. Chetan Shah, Managing Director, will transition to a non-executive role and is proposed to be appointed Chairman. Dr. Suresh Ramachandran, currently Deputy Managing Director, will be elevated to Managing Director. The company also announced plans to restart the distribution of animal nutrition products following a prior discontinuation, driven by global supply chain challenges and customer demand, though the profitability of this segment is expected to remain limited.